Free Trial
→ You won’t believe where OpenAI billionaire is investing now (From Wealthpin Pro) (Ad)

Femasys Q1 2023 Earnings Report

Femasys logo
$1.18 -0.01 (-0.84%)
As of 01/31/2025 04:00 PM Eastern
Earnings HistoryForecast

Femasys EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q1 2023
Date
5/11/2023
Time
N/A

Conference Call Resources

Femasys Earnings Headlines

Femasys announces notices of intention to grant 2 European patent applications
January 31 at 6:46 PM | markets.businessinsider.com
Femasys Inc.: Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
January 30 at 2:08 PM | finanznachrichten.de
You won’t believe where OpenAI billionaire is investing now
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.
February 1, 2025 | Wealthpin Pro (Ad)
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
January 30 at 8:30 AM | globenewswire.com
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
January 16, 2025 | globenewswire.com
Femasys’s Strategic Partnerships and Market Expansion Drive Buy Rating
December 5, 2024 | markets.businessinsider.com
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

View Femasys Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles